142 related articles for article (PubMed ID: 2478221)
1. Modulation of arabinosylcytosine metabolism by arabinosyl-2-fluoroadenine in lymphocytes from patients with chronic lymphocytic leukemia: implications for combination therapy.
Gandhi V; Nowak B; Keating MJ; Plunkett W
Blood; 1989 Nov; 74(6):2070-5. PubMed ID: 2478221
[TBL] [Abstract][Full Text] [Related]
2. Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia.
Gandhi V; Kemena A; Keating MJ; Plunkett W
Cancer Res; 1992 Feb; 52(4):897-903. PubMed ID: 1737352
[TBL] [Abstract][Full Text] [Related]
3. Cell cycle-specific metabolism of arabinosyl nucleosides in K562 human leukemia cells.
Gandhi V; Plunkett W
Cancer Chemother Pharmacol; 1992; 31(1):11-7. PubMed ID: 1458554
[TBL] [Abstract][Full Text] [Related]
4. Combination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia: clinical efficacy and modulation of arabinosylcytosine pharmacology.
Gandhi V; Robertson LE; Keating MJ; Plunkett W
Cancer Chemother Pharmacol; 1994; 34(1):30-6. PubMed ID: 8174200
[TBL] [Abstract][Full Text] [Related]
5. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
Gandhi V; Estey E; Du M; Nowak B; Keating MJ; Plunkett W
Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
[TBL] [Abstract][Full Text] [Related]
6. Biochemical modulation of arabinosylcytosine for therapy of leukemias.
Gandhi V; Estey E; Keating MJ; Plunkett W
Leuk Lymphoma; 1993; 10 Suppl():109-14. PubMed ID: 8481660
[TBL] [Abstract][Full Text] [Related]
7. Interaction of arabinosyl nucleotides in K562 human leukemia cells.
Gandhi V; Plunkett W
Biochem Pharmacol; 1989 Oct; 38(20):3551-8. PubMed ID: 2479383
[TBL] [Abstract][Full Text] [Related]
8. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
Gandhi V; Estey E; Du M; Keating MJ; Plunkett W
Clin Cancer Res; 1997 Sep; 3(9):1539-45. PubMed ID: 9815841
[TBL] [Abstract][Full Text] [Related]
9. Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells.
Gandhi V; Plunkett W
Cancer Res; 1988 Jan; 48(2):329-34. PubMed ID: 3335008
[TBL] [Abstract][Full Text] [Related]
10. Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule.
Seymour JF; Huang P; Plunkett W; Gandhi V
Clin Cancer Res; 1996 Apr; 2(4):653-8. PubMed ID: 9816215
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of fludarabine metabolism by arabinosylcytosine during therapy.
Kemena A; Gandhi V; Shewach DS; Keating M; Plunkett W
Cancer Chemother Pharmacol; 1992; 31(3):193-9. PubMed ID: 1464155
[TBL] [Abstract][Full Text] [Related]
12. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy.
Gandhi V; Estey E; Keating MJ; Plunkett W
J Clin Oncol; 1993 Jan; 11(1):116-24. PubMed ID: 8418222
[TBL] [Abstract][Full Text] [Related]
13. Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemia.
Danhauser L; Plunkett W; Liliemark J; Gandhi V; Iacoboni S; Keating M
Leukemia; 1987 Sep; 1(9):638-43. PubMed ID: 3478543
[TBL] [Abstract][Full Text] [Related]
14. Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy.
Plunkett W; Liliemark JO; Adams TM; Nowak B; Estey E; Kantarjian H; Keating MJ
Cancer Res; 1987 Jun; 47(11):3005-11. PubMed ID: 3471322
[TBL] [Abstract][Full Text] [Related]
15. Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions.
Gandhi V; Estey E; Keating MJ; Chucrallah A; Plunkett W
Blood; 1996 Jan; 87(1):256-64. PubMed ID: 8547650
[TBL] [Abstract][Full Text] [Related]
16. Cellular pharmacology of fludarabine triphosphate in chronic lymphocytic leukemia cells during fludarabine therapy.
Gandhi V; Kemena A; Keating MJ; Plunkett W
Leuk Lymphoma; 1993 May; 10(1-2):49-56. PubMed ID: 8374523
[TBL] [Abstract][Full Text] [Related]
17. Effect of amsacrine on ara-CTP cellular pharmacology in human leukemia cells during high-dose cytarabine therapy.
Plunkett W; Nowak B; Keating MJ
Cancer Treat Rep; 1987 May; 71(5):479-83. PubMed ID: 3567973
[TBL] [Abstract][Full Text] [Related]
18. 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma.
Danhauser L; Plunkett W; Keating M; Cabanillas F
Cancer Chemother Pharmacol; 1986; 18(2):145-52. PubMed ID: 2431803
[TBL] [Abstract][Full Text] [Related]
19. Pharmacologically directed design of leukemia therapy.
Plunkett W; Heinemann V; Estey E; Keating M
Haematol Blood Transfus; 1990; 33():610-3. PubMed ID: 2182451
[TBL] [Abstract][Full Text] [Related]
20. Saturation of ara-CTP accumulation during high-dose ara-C therapy: pharmacologic rationale for intermediate-dose ara-C.
Plunkett W; Liliemark JO; Estey E; Keating MJ
Semin Oncol; 1987 Jun; 14(2 Suppl 1):159-66. PubMed ID: 3589690
[No Abstract] [Full Text] [Related]
[Next] [New Search]
